Find us

+48 221 201 690

info@swisslaser.pl

Leczenie Zespołu Suchego Oka OptiLight

OptiLIGHT technology, developed by Lumenis, a pioneer in IPL technology, provides an innovative solution for treating Dry Eye Syndrome (DSO) caused by Meibomian gland dysfunction (MGD). OptiLIGHT is the first and only IPL therapy approved by the FDA for such use. A key feature of this technology is the use of patented Optimal Pulse Technology (OPT™), which enables the precise and controlled delivery of the light energy required for effective treatment. The procedure is safe and precise.

Leczenie Zespołu Suchego Oka OptiLight

The OptiLIGHT device is designed for the comfort of both patients and operators. Ergonomic handles and adjustable settings allow the device to adapt to the individual curve and contour of the face. OptiLIGHT is equipped with safety systems that protect the patient’s eyes from possible side effects. Special protective goggles used during the procedure and a cooling gel applied to the skin minimize discomfort and protect the tissue.

How does the procedure work?

  • The procedure begins with the preparation of the patient, who sits in the treatment chair and puts on protective goggles.
  • This is followed by a thorough cleansing of the eyelids to remove any impurities such as dirt, dandruff or makeup residue, which is essential for the safety and effectiveness of the treatment.
  • The next step is the application of a special cooling gel, which acts as a protective layer and provides comfort during the procedure.
  • Then, using a special IPL head, short, intense flashes of light are emitted. The light penetrates deep into the tissues, reducing inflammation, dissolving clumped secretions from Meibom’s glands and reducing pathogenic bacteria and mites on the eyelid margins.

The treatment takes about 15 minutes and usually requires several sessions (usually 3-4) at 2-3 week intervals to achieve significant improvement.

OptiLIGHT technology, using Intense Pulsed Light (IPL), is widely recognized as a safe and non-invasive treatment for Dry Eye Syndrome caused by Meibomian gland dysfunction. The FDA, the U.S. Food and Drug Administration, has approved the technology, demonstrating its high standard of safety and effectiveness.

During the OptiLIGHT procedure, the patient experiences minimal discomfort, and the process is designed to minimize the risk of unpleasant sensations. Most patients can return to their daily activities immediately after the procedure, indicating that there is no need for convalescence.

However, as with many medical procedures, there is the possibility of adverse reactions. Although they are rare, patients may experience temporary redness, mild swelling, pain or discomfort, as well as changes in skin pigmentation or dryness. In extreme cases, scarring or burns can occur, so it is important that the procedure is carried out by an experienced and certified specialist who can properly manage the light energy of the device and monitor the patient’s skin reaction during the procedure.

OptiLIGHT is an excellent option for those looking for an effective treatment option for IOP, but like any medical procedure, it requires informed consent after the patient has been properly informed of all aspects of the treatment, including potential risks.

Zapisz się na niezobowiązująca wizytę i konsultację, na której dowiesz się, jak możemy poprawić Twój wzrok.

 

Zobacz jak się umówić